Inhibrx
INBX
92 hedge funds and large institutions have $151M invested in Inhibrx in 2025 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 36 reducing their positions, and 15 closing their positions.
351% more call options, than puts
Call options by funds: $993K | Put options by funds: $220K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.59% less ownership
Funds ownership: 77.11% → 74.52% (-2.6%)
9% less funds holding
Funds holding: 101 → 92 (-9)
12% less capital invested
Capital invested by funds: $172M → $151M (-$21M)
47% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 15
50% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$4.87M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$4.12M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$2.32M |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
+$1.22M |
| 5 |
GLF
Groupe la Francaise
Paris,
France
|
+$1.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$8.93M |
| 2 |
CP
Castalian Partners
Excelsior,
Minnesota
|
-$2.95M |
| 3 |
SC
Slotnik Capital
Dallas,
Texas
|
-$1.37M |
| 4 |
Jane Street
New York
|
-$844K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$825K |
INBX Hedge Fund Activity: Q1 2025 in Review
92 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Inhibrx (INBX) for Q1 2025, worth a combined $151M — down 12% from $172M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of INBX and 8 opened new positions — a net loss of 7 holders — while 36 trimmed existing stakes and 18 added.
The largest buyer was Woodline Partners, opening a new position worth an estimated $4.87M. The largest seller was Walleye Capital, exiting entirely with an estimated $8.93M sold.
- 92 institutional investors held Inhibrx (INBX) as of Q1 2025, down from 101 in Q4 2024.
- Funds reported $151M of Inhibrx stock for Q1 2025, down 12% quarter-over-quarter.
- 8 funds opened new Inhibrx positions in Q1 2025 and 15 closed out, a net change of -7 holders.
- The largest Inhibrx buyer in Q1 2025 was Woodline Partners, an estimated $4.87M added.
- The largest Inhibrx seller in Q1 2025 was Walleye Capital, an estimated $8.93M sold.
Based on aggregated 13F filings for Q1 2025.